At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 82 enrolled
Drug / intervention
Boostrix TMbiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Evaluation of GSK Biologicals' dTpa Booster Vaccine in Young Adults 10 Years After Previous dTpa Boosting.
In Brief
A Phase 4 clinical trial evaluating Boostrix TM for Acellular Pertussis and 2 related conditions. Completed, enrolled 82 participants across 1 site.
Detailed Summary
The purpose of this study is to assess the efficacy and safety of repeating dTpa booster in adults 10 years after previous booster vaccination with dTpa in a prior clinical study. Only subjects who received booster vaccination in the previous clinical study are eligible for participation in this study.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAcellular Pertussis, Tetanus, Diphtheria
CountriesFinland
Collaborators--
Timeline
Phase 4CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartJan 2008
First PostedFeb 2008
Primary CompletionApr 2008
TodayJul 2026
First PostedFeb 7, 2008
Enrollment StartJan 1, 2008
Primary CompletionApr 30, 2008
TodayJul 2, 2026
Enrollment to primary: 4 monthsPosted 18.4 years ago
Interventions
Boostrix TMbiological
Single booster dose of vaccine